Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms, Unknown Primary × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 32 Breast Neoplasms 23 Triple Negative Breast Neoplasms 16 Prostatic Neoplasms 15 Fallopian Tube Neoplasms 11 Neoplasms 8 Pancreatic Neoplasms 6 Glioma 6 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Fanconi Anemia, Complementation Group D1 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Neoplasm Metastasis 3 Medulloblastoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Wilms Tumor 2 Uveal Melanoma 2

Interventions

Gemcitabine 8 Carboplatin 8 Paclitaxel 6 Capecitabine 4 Irinotecan 3 Bevacizumab 3 pembrolizumab 2 atezolizumab 2 Peripheral Blood Stem Cell Transplantation 2 Oxaliplatin 2 Filgrastim 2 Erlotinib Hydrochloride 2 Cisplatin 2 CP protocol 2 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 entrectinib 1 cobimetinib 1 belinostat 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Transurethral Resection of Prostate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡